CLYM
Climb Bio·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About CLYM
Climb Bio, Inc.
A clinical-stage biotechnology company developing treatments for patients with immune-mediated diseases
20 William Street, Suite 145, Wellesley Hills, MA 02481
--
Climb Bio, Inc., was incorporated as a Delaware corporation on October 18, 2018. The company is a biotechnology company focused on developing novel therapies for neuronal excitatory disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and peripheral and central nervous system diseases.
Earnings Call
Q3/2025
Estimate EPS-0.14
Actual EPS-0.19
Estimate Revenue--
Actual Revenue0
Climb's Q3 2025 Earnings Call: Contradictions Emerge on Tariffs, Currency Fluctuations, Margins, and DSS Seasonality
Oct 30,2025 12:28
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
CLYM has released its 2025 Q3 earnings. EPS was reported at -0.19, versus the expected -0.14, missing expectations. The chart below visualizes how CLYM has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
